NuriBio Overview

  • Founded
  • 2014
  • Status
  • Private
  • Latest Deal Type
  • Accelerator/​Inc
  • Investors
  • 1

NuriBio General Information


Provider of a pharmaceutical platform intended to improve the quality of human life through genetic analysis technology. The company's platform is based on a real-time polymerase chain reaction that monitors the amplification of a targeted DNA molecule, enabling businesses to diagnose various diseases such as Alzheimer's disease and Parkinson's disease.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
  • 66 Beolmal-ro, Dongan-gu
  • F105 7 Hifield
  • Anyang, Gyeonggi-do
  • South Korea
+82 000-000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

NuriBio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Accelerator/Incubator 01-Jun-2018 Completed Generating Revenue
To view NuriBio’s complete valuation and funding history, request access »

NuriBio Executive Team (1)

Name Title Board Seat Contact Info
Younghyean Nam Chief Executive Officer
To view NuriBio’s complete executive team members history, request access »

NuriBio Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Tech Incubator Program for Startups Accelerator/Incubator Minority 000 0000 000000 0
To view NuriBio’s complete investors history, request access »